Stock 688166 BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News BrightGene Bio-Medical Technology Co., Ltd.

Equities

688166

CNE100003PR1

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 30/05/2024 BST 		5-day change 1st Jan Change
35.53 CNY -1.93% Intraday chart for BrightGene Bio-Medical Technology Co., Ltd. -0.59% +1.51%
05-07 China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7% MT
05-07 BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3% MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7%
MT
BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3%
MT
BrightGene Bio-Medical Technology Co., Ltd. announced that it expects to receive CNY 499.999987 million in funding
CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Tranche Update on BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.
CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
BrightGene Bio-Medical Technology Co., Ltd. announces an Equity Buyback for CNY 20 million worth of its shares.
CI
BrightGene Bio-Medical Technology Co., Ltd. authorizes a Buyback Plan.
CI
Oralead Pharma announced that it has received funding from HighLight Capital, Shenzhen Qianhai BangQin Investment Co., Ltd., BrightGene Bio-Medical Technology Co., Ltd., Shenyang Borui Pharmaceutical Co., Ltd.
CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Chinese Regulator Issues Warning Against BrightGene Bio-Medical Chairman Over Weight Loss Claims
MT
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs
MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
BrightGene Bio-Medical Technology's Unit Gets Hospital's Approval for Diabetes Drug Trial
MT
Chinese Drug Regulator Certifies Two Drugs of BrightGene's Unit
MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
BrightGene Bio-Medical to Hike Investment in API Production Project to 500 Million Yuan
MT
Xinchuang Biomedical Technology Subsidiary Gets Nod to Hold Anti-Diabetes Drug Trial
MT
BrightGene Bio-Medical Technology Co., Ltd. announced that it has received CNY 226.613082 million in funding from Horizon Asset Management Co. Ltd., Shanghai Leitu Asset Management Co., Ltd. and other investors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 688166 Stock
  4. News BrightGene Bio-Medical Technology Co., Ltd.